Target Audience and Goal Statement
This activity is intended for oncologists, urologists, and other healthcare professionals involved in the management of men
with metastatic castration-resistant prostate cancer (mCRPC).
The goal of this activity is to review the current paradigm of mCRPC management including data on the safety, efficacy, and
potential benefit of molecularly targeted therapies, and learn about the necessary tools for considering how new targeted
therapy approaches might be effectively incorporated into the future treatment paradigm for patients with mCRPC.
Upon completion of this activity, participants will be able to:
- Recognize the benefits and limitations of current therapies for men with CRPC
- Outline the role of the Src signaling pathway in the development and progression of CRPC
- Evaluate clinical trial data on molecularly targeted agents in the management of patients with mCRPC
- Describe how to target bone development and function to delay or avoid bone metastasis (Src, RANKL, FGF, Met)
- Discuss challenges of integrating new therapies with distinct mechanisms of action (immunotherapy, bone-targeting, chemotherapy,
molecularly targeted agents) to maximize outcomes
Disclosures
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of
an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant
financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial
relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food
and Drug Administration, at first mention and where appropriate in the content.
Authors
-
Christopher J. Logothetis, MD
Chairman/Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Disclosures
Disclosure: Christopher J. Logothetis, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Amgen Inc.; Novartis Pharmaceuticals Corporation; Johnson
& Johnson Pharmaceutical Research & Development, L.L.C.
Dr Logothetis does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Logothetis does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
-
Tomasz M. Beer, MD
Professor of Medicine, Staff Physician, Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon
Disclosures
Disclosure: Tomasz M. Beer, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Centocor, Inc.; Ortho Biotech Products, L.P.; Dendreon Corp.; GTx, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Cell Therapeutics, Inc.; Cougar Biotechnology, Inc.;
Dendreon Corp.; ImClone Systems Incorporated; Medivation, Inc.; Novartis Pharmaceuticals Corporation; OncoGenex Pharmaceuticals
Inc.
Provided expert testimony for: Novartis Pharmaceuticals Corporation
Dr Beer does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Beer does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
-
Johann S. de Bono, MD, PhD
Professor of Experimental Cancer Medicine, University of London, Institute of Cancer Research; Honorary Consultant, Royal
Marsden NHS Trust, Sutton, Surrey, UK
Disclosures
Disclosure: Johann S. de Bono, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Cougar Biotechnology, Inc.; Johnson & Johnson Pharmaceutical Research & Development,
L.L.C.; AstraZeneca Pharmaceuticals LP; Medivation, Inc.; Astellas Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;
sanofi-aventis
Received grants for clinical research from: Pfizer Inc Employed by a commercial interest: Institute of Cancer Research
Dr de Bono does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr de Bono does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
-
Fred Saad, MD
Professor and Chair of Urology, University of Montreal; Chief, Division of Urology, University of Montreal Hospital Center,
Montreal, Canada
Disclosures
Disclosure: Fred Saad, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Products,
L.P; sanofi-aventis
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica
Products, L.P; sanofi-aventis
Received grants for clinical research from: Amgen Inc.; Cougar Biotechnology, Inc.; Medivation, Inc.; Bristol-Myers Squibb
Company
Dr Saad does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Saad does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Editors
CME Reviewer
Accreditation Statements
For Physicians
-
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical
education for physicians.
Medscape, LLC designates this enduring material for a maximum of 2.0
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Contact This Provider
For questions regarding the content of this activity, contact the
accredited provider for this CME/CE activity noted above. For technical
assistance, contact [email protected]
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or printed out.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated
at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
